The statutory health insurance funds in Germany warn of an accelerating increase in drug prices due to planned interventions by US President Donald Trump and call for immediate reforms in pricing regulation. “The price spiral for patented drugs is also spinning out of control here in Germany” said Carola Reimann, head of the AOK-Bundesverbands, to the “Redaktionsnetzwerk Deutschland” (Wednesday editions). “It is not impossible that the price pressure in Germany will be further intensified by the measures in the US” she said. However, Germany has a “very innovative” approach to drug supply, said Reimann. “Unfortunately, it can now be seen that the pharmaceutical industry is exploiting this to an excessive extent” she criticized. Therefore, the AOK head immediately demanded reforms in pricing regulation. “To stabilize the finances of statutory health insurance sustainably and not burden contributors even more, we must urgently get a grip on drug prices” said Reimann. “Only then can the upward trend in costs be effectively curbed.
Trump’s US interventions could lead to higher drug prices in Germany
